Amgen (AMGN) BidaskScore is downgraded to Strongly Sold

Amgen, Inc.

The BidaskScore of Amgen Inc. AMGNAMGN shows that the shares of the company are now AMGNStrongly Bought Strongly Sold by investors.

The BidaskScore of the BiotechnologyBiotechnology shows that the sector is BiotechnologyStrongly Bought Sold since January 23.

Here are the BidAskScore of other related companies in the Biotechnology sector:

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture and marketing of human therapeutics. Its products include the following brands: Aranesp, BLINCYTO, Corlanor, ENBREL, EPOGEN, IMLYGIC, KYPROLIS, Neulasta, NEUPOGEN, Nplate, Parsabiv, Prolia, Repatha, Sensipar, Vectibix, and XGEVA. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

Amgen, Inc.

Launched in 2016, the BidAskClubBidaskClub allows users to follow the evolution of the US equity market. BidaskClub provides a platform to create portfolios and be informed when a company´s or sector’s BidaskScore changes. BidaskClub is provided by LuxFinAdviceLuxFinAdvice.